현대바이오

Business Overview

Hyundai BioScience, established in 2000 as a spin-off from Hyundai Electronics, specializes in bio-pharmaceuticals and cosmeceuticals, focusing on new drug development and functional cosmetics. After shutting down its IT business in 2018 and rebranding, the company expanded its R&D and production network through overseas joint ventures in Japan and the U.S., prioritizing the development of antiviral treatments and cancer drugs. However, it reported a revenue of 35 billion won, along with an operating loss of 18.2 billion won and a net loss of 22.1 billion won in its latest financial statements.